Velcade

(bortezomib)

ApprovedSmall molecule

Bortezomib is used to treat certain types of cancer, including multiple myeloma (a blood cancer) and mantle cell lymphoma. It works by blocking proteins that help cancer cells survive and grow.[2] Velcade is currently approved and in use across 99 indications[4].[1]

Velcade is one of 1634 small molecule programs targeting Glioma. It is currently in Approved.

Indications

745

Total Trials

Active Trials

1,633

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

Acquired HemophiliaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Bronchiolitis ObliteransApproved

Non-Hodgkins LymphomaApproved

PlasmacytomaActive, not recruiting

Prostate NeoplasmApproved

Primary Systemic AmyloidosisActive, not recruiting

B-Cell NeoplasmActive, not recruiting

GliomaPhase 1

Active, not recruiting

Childhood Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

Acquired HemophiliaPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Bronchiolitis ObliteransApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

PlasmacytomaPhase 2

Active, not recruiting

Prostate NeoplasmApproved

Approved

Primary Systemic AmyloidosisPreclinical

Active, not recruiting

B-Cell NeoplasmPhase 1

Active, not recruiting

Showing 10 of 98 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Velcade

SShilpa Grover, MD, MPH

Approved

4 2

Trodelvy

Gilead

Preclinical

37 3

Tykerb

GSK

Preclinical

80 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Bisphosphonate

Amgen

Preclinical

2 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

AL Amyloidosis

NCT04754945

Post-ApprovalRecruiting

Peripheral Neuropathy

NCT07025005

Q4 2026

Phase 1Active, not recruiting

Multiple Myeloma

NCT04091126

Post-ApprovalRecruiting

Children

NCT03844360

Q3 2027

Phase 3Active, not recruiting

Multiple Myeloma

NCT04751877

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT05514990

Clinical

Trials by Indication[1]

Multiple Myeloma97 trials

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00310024·40 enrolled

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Unknown status·OOncotherapeutics·Phase 2·NCT00742404·35 enrolled

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00813150·96 enrolled

Show 94 more trials

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01818752·955 enrolled

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04091126·118 enrolled

UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 2·NCT01313897·10 enrolled

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

Completed·UUniversity of Turin, Italy·Phase 2·NCT00358020·30 enrolled

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00401843·307 enrolled

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05572515·614 enrolled

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

Withdrawn·UUniversity of Miami·Phase 1·NCT00504101

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·OOncotherapeutics·Phase 2·NCT00317811·35 enrolled

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00773747·637 enrolled

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Terminated·EEmory University·Phase 1/2·NCT00793650·39 enrolled

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04975997·864 enrolled

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Completed·—·Phase 2·NCT00153920·66 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01038388·30 enrolled

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00084747·30 enrolled

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT02254551·7 enrolled

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01711528·41 enrolled

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Washington·Phase 1/2·NCT00849251·31 enrolled

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00719901·11 enrolled

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00609167·63 enrolled

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT00972712·12 enrolled

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT04802356·50 enrolled

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Withdrawn· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00706953

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT01063179·511 enrolled

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Terminated·LLa Jolla Pharmaceutical Company·Phase 1·NCT00609817·9 enrolled

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01556438·16 enrolled

Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 3·NCT01530594·440 enrolled

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00561743·50 enrolled

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

Completed·MMaisonneuve-Rosemont Hospital·Phase 2·NCT02308280·40 enrolled

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Completed·IIntergroupe Francophone du Myelome·Phase 3·NCT02541383·1,085 enrolled

Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01208818·284 enrolled

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Completed·GGrupo de Estudos Multicentricos em Onco-Hematologia·Phase 3·NCT03402295·311 enrolled

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

Completed·UUniversity Hospital, Toulouse·Phase 3·NCT02197221·300 enrolled

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Completed·HHackensack Meridian Health·Phase 1/2·NCT00784823·32 enrolled

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00750815·58 enrolled

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Completed· Pfizer logo

Pfizer·Phase 1·NCT01248923·55 enrolled

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Recruiting·UUppsala University··NCT06245629·100 enrolled

Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma

Unknown status·SSamsung Medical Center·Phase 2·NCT04277845·49 enrolled

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

Completed·TThe First Affiliated Hospital of Soochow University··NCT07206810·419 enrolled

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00440635·641 enrolled

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Completed·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT01208766·1,503 enrolled

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Unknown status·SSecond Military Medical University·Phase 4·NCT01249690·100 enrolled

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 2·NCT00531453·98 enrolled

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT03314181·156 enrolled

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Completed· GSK logo

GSK·Phase 1/2·NCT03544281·153 enrolled

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·OOncotherapeutics·Phase 1·NCT00316940·36 enrolled

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00335348·101 enrolled

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Not yet recruiting· Regeneron logo

Regeneron·Phase 2/3·NCT07428369·1,570 enrolled

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT00048230·620 enrolled

Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01026701·104 enrolled

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Completed·SSellas Life Sciences Group·Phase 1/2·NCT01827137·20 enrolled

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Recruiting·—·Phase 2·NCT06505369·50 enrolled

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Terminated·HHackensack Meridian Health·Phase 2·NCT01453088·63 enrolled

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Completed·PPETHEMA Foundation·Phase 2·NCT00564200·30 enrolled

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Unknown status·—·Phase 2·NCT00389701·30 enrolled

Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00570180·36 enrolled

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT05849610·30 enrolled

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02474563·171 enrolled

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

Completed·MMassachusetts General Hospital·Phase 2·NCT01782963·50 enrolled

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02773030·466 enrolled

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01647165

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT00111319

Two Schemes Response in Multiple Myeloma

Recruiting·HHospital General de Mexico··NCT06284395·83 enrolled

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting·—·Phase 2/3·NCT05665140·100 enrolled

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Unknown status·UUniversity of Wuerzburg·Phase 2·NCT00311337·61 enrolled

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01440582·77 enrolled

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00718640·10 enrolled

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT07018050·160 enrolled

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Completed· Takeda logo

Takeda·Phase 4·NCT00257114

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Completed· Otsuka logo

Otsuka·Phase 2·NCT01009840·30 enrolled

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT02268890·18 enrolled

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT03701321

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00416208·154 enrolled

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00334932·32 enrolled

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT05392946·49 enrolled

Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Withdrawn·UUniversity of Florida·Phase 1·NCT01680796

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Active, not recruiting·UUniversity of Southern California·Phase 1/2·NCT05514990·10 enrolled

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting· Takeda logo

Takeda·Phase 1·NCT03984097·50 enrolled

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Unknown status·FFred Hutchinson Cancer Center·Phase 2·NCT00438841·43 enrolled

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Terminated·AAbdullah Khan·Phase 1·NCT04956302·1 enrolled

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Completed·—·Phase 2·NCT02441686·46 enrolled

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·CCancer Trials Ireland·Phase 2·NCT05123131·54 enrolled

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT01863550·1,087 enrolled

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated·WWashington University School of Medicine·Phase 1·NCT04912427·1 enrolled

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT00483262·63 enrolled

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

Unknown status·—··NCT04678089·350 enrolled

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02555839·127 enrolled

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Terminated· Bayer logo

Bayer·Phase 1/2·NCT02928029·7 enrolled

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 3·NCT02362165·236 enrolled

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Active, not recruiting·PPoitiers University Hospital·Phase 3·NCT04751877·270 enrolled

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Terminated·AAB Science·Phase 3·NCT01470131·147 enrolled

Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study

Unknown status·YYonsei University·Phase 1/2·NCT01255527·53 enrolled

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·—·Phase 1·NCT00568880·25 enrolled

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01919086·30 enrolled

Lymphoma12 trials

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Completed·PPierluigi Porcu·Phase 1·NCT01129180·8 enrolled

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00967369·20 enrolled

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT00093704·1 enrolled

Show 9 more trials

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Terminated·RRush University Medical Center·Phase 2·NCT00479167·1 enrolled

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

Completed·WWeill Medical College of Cornell University·Phase 1·NCT00777114·31 enrolled

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT00312845·676 enrolled

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00093769·15 enrolled

A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

Completed·IIstituto Clinico Humanitas·Phase 2·NCT00636311·13 enrolled

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00096005·36 enrolled

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 1·NCT00598169·23 enrolled

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04061772·54 enrolled

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·NNYU Langone Health·Phase 1·NCT00004002

Mantle Cell Lymphoma7 trials

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Completed·AAnand Jillella·Phase 1·NCT01504776·3 enrolled

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Completed·SSeoul National University Hospital·Phase 2·NCT02840539·19 enrolled

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Unknown status·MMedical University of Vienna·Phase 2·NCT00261612·16 enrolled

Show 4 more trials

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Completed·UUniversity Hospital Plymouth NHS Trust·Phase 2·NCT00513955·50 enrolled

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Completed·UUniversity of Arizona·Phase 2·NCT00980395·24 enrolled

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00114738·53 enrolled

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00377052·29 enrolled

Dexamethasone4 trials

Microdose Study of Melphalan, Bortezomib and Dexamethasone

Unknown status·HHenrik Gregersen·Phase 1·NCT02109861·6 enrolled

Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Completed·TTampere University Hospital·Phase 2/3·NCT00861250·47 enrolled

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Unknown status·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT05052970·60 enrolled

Show 1 more trial

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

No longer available· Takeda logo

Takeda··NCT00063791

Non-Small Cell Lung Cancer4 trials

Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer

Withdrawn·UUniversity of Southern California·Phase 1/2·NCT00313690

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075751·99 enrolled

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00040768·35 enrolled

Show 1 more trial

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00052338·34 enrolled

61 more indications

Patients With Advanced Solid Tumors3 trials

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00620295·17 enrolled

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00541359·54 enrolled

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00622674·37 enrolled

AL amyloidosis3 trials

Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Not yet recruiting·—·Phase 3·NCT05776940·116 enrolled

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Active, not recruiting·EEmory University·Phase 1·NCT04754945·11 enrolled

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Completed·NNanjing University School of Medicine·Phase 3·NCT01998503·56 enrolled

Follicular Lymphoma2 trials

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Terminated·NNorthwestern University·Phase 1/2·NCT00372905·18 enrolled

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Terminated·—·Phase 2·NCT00510887·14 enrolled

Acute Lymphoblastic Leukemia2 trials

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00440726·31 enrolled

Chronic Lymphocytic Leukemia2 trials

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed· Gilead logo

Gilead·Phase 1·NCT01088048·241 enrolled

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00068315·18 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma

Completed·SSingapore General Hospital·Phase 1·NCT01226849·6 enrolled

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01848132·121 enrolled

Leukemia2 trials

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00410423·55 enrolled

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

Terminated·RReuven Schore·Phase 1·NCT02484261·10 enrolled

Acute Graft Versus Host Disease2 trials

A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients

Completed·IIndiana University·Phase 1·NCT01926899·15 enrolled

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

Completed·—·Phase 1·NCT00670423·27 enrolled

Acute Myeloid Leukemia2 trials

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01420926·165 enrolled

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00703300·19 enrolled

Amyloidosis2 trials

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00458822·40 enrolled

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Completed·—·Phase 2·NCT01083316·35 enrolled

Macroglobulinemia2 trials

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02844322·35 enrolled

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1/2·NCT01125293·46 enrolled

Kidney Transplant2 trials

Desensitization in Kidney Transplantation

Completed·UUniversity of Cincinnati·Phase 4·NCT00908583·44 enrolled

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

Completed·MMedical University of Vienna·Phase 2·NCT01873157·44 enrolled

Relapsed or Refractory2 trials

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Withdrawn·—·Phase 1·NCT02658396

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01016730·24 enrolled

Advanced Malignancies1 trial

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00068484·25 enrolled

Allograft1 trial

The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

Completed·MMayo Clinic·Phase 2·NCT00722722·18 enrolled

TED1 trial

Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT01863004·3 enrolled

Hypophosphatasia1 trial

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT06015750

Maintenance Therapy1 trial

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

Refractory1 trial

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Recruiting·NNanjing IASO Biotechnology Co., Ltd.·Phase 3·NCT06464991·240 enrolled

Immune Thrombocytopenia1 trial

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

Recruiting·SSeoul National University Hospital·Phase 2·NCT05599880·29 enrolled

Other Solid Tumors1 trial

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

Completed·—·Phase 1·NCT00544284·25 enrolled

Hematologic Malignancies1 trial

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02419755·12 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Glioblastoma Multiforme1 trial

Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00998010·24 enrolled

Efficacy and Safety1 trial

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

Terminated·UUniversity of Massachusetts, Worcester·Phase 1·NCT00424840·12 enrolled

Peripheral Neuropathy1 trial

Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

Recruiting·TTanta University·Phase 4·NCT07025005·44 enrolled

Chemotherapy1 trial

Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00504751·15 enrolled

Glioma1 trial

Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)

Unknown status·HHaukeland University Hospital·Phase 1/2·NCT03643549·63 enrolled

First-line Treatment1 trial

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04423367·18 enrolled

Waldenstrom macroglobulinemia1 trial

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02371148·38 enrolled

Cutaneous T-cell lymphoma1 trial

Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT03487133·32 enrolled

Solid Tumors1 trial

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02211755·28 enrolled

Heart Transplant1 trial

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Terminated·PProvidence Health & Services·Phase 2·NCT01556347·2 enrolled

EBV1 trial

Bortezomib Plus Rituximab for EBV+ PTLD

Completed·MMassachusetts General Hospital·Phase 2·NCT01058239·7 enrolled

Plasma Cell Leukemia1 trial

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Unknown status·CClinical Service, China·Phase 2·NCT01328236·20 enrolled

Advanced NSCLC1 trial

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Unknown status·AAptium Oncology Research Network·Phase 1/2·NCT00516100·62 enrolled

Rheumatoid Arthritis1 trial

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Unknown status·CChinese SLE Treatment And Research Group·N/A·NCT05805891·20 enrolled

Renal Failure1 trial

Optimising Renal Outcome in Myeloma Renal Failure

Completed·OOxford University Hospitals NHS Trust·Phase 2·NCT02424851·31 enrolled

Graft Vs Host Disease1 trial

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

Unknown status·—·Phase 2·NCT01158105·25 enrolled

Renal insufficiency1 trial

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

Recruiting·MMedical College of Wisconsin·Phase 2·NCT04240054·41 enrolled

Soft Tissue Sarcoma1 trial

Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00937495·16 enrolled

Treatment1 trial

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Recruiting·—·Phase 2·NCT03590171·250 enrolled

Kidney Cancer1 trial

PS-341 in Treating Patients With Metastatic Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00017329

Trial1 trial

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed· Astellas logo

Astellas·Phase 2·NCT02057380·13 enrolled

Bone Marrow Cancer1 trial

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Completed·VVejle Hospital·Phase 2·NCT00436059·20 enrolled

Patients With Solid Tumors1 trial

Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT02220049·18 enrolled

Children1 trial

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Metastatic1 trial

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00066352

Neuroblastoma1 trial

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Completed·GGiselle Sholler·Phase 1/2·NCT02139397·16 enrolled

Newly Diagnosed1 trial

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Completed·—·Phase 2·NCT02375555·40 enrolled

Melanoma1 trial

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT01462773·16 enrolled

Complication1 trial

Bortezomib to Treat Significant Complication of HSCT

Completed·—·Phase 2·NCT01929980·4 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Recruiting·HHenry Ford Health System·Phase 2·NCT03850366·15 enrolled

Daratumumab1 trial

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Terminated·OOncopeptides AB·Phase 1/2·NCT03481556·56 enrolled

Intrahepatic Cholangiocellular Carcinoma1 trial

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Unknown status·ZZhengang Yuan·Phase 3·NCT03345303·50 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Myelodysplastic Syndromes1 trial

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Completed·UUniversity of Rochester·Phase 2·NCT00262873·8 enrolled

Transplantation1 trial

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT00642395·61 enrolled

Myeloma1 trial

Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

Completed·KKarin B. Ø. Dieperink··NCT05163405·10 enrolled

Malignant Solid Tumors1 trial

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00667641·16 enrolled

Unspecified1 trial

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Recruiting·UUniversity of Heidelberg Medical Center·Phase 2·NCT05695508·160 enrolled

Regulatory

FDA Approval Timeline[5]

May 13, 2003

VELCADE

NDA NDA021602

Nov 6, 2017

BORTEZOMIB

NDA NDA205004

Oct 4, 2019

BORTEZOMIB

NDA NDA206927

May 2, 2022

BORTEZOMIB

NDA NDA209191

Jul 26, 2022

BORTEZOMIB

NDA NDA215441

Jul 27, 2022

BORTEZOMIB

NDA NDA215331

Aug 26, 2024

BORTEZOMIB

NDA NDA212782

Sources

References

[1]
ClinicalTrials.gov — 745 trial records for bortezomib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Velcade drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — bortezomib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for bortezomib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA212782). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Velcade. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Shilpa Grover, MD, MPH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SShilpa Grover, MD, MPH

Patent Landscape[6]

Patent Cliff

Nov 3, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8962572Nov 3, 2032

11752164Sep 23, 2042

11679119Sep 23, 2042

12005069Sep 23, 2042

Velcade

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Trials by Indication[1]

Multiple Myeloma97 trials

Lymphoma12 trials

Mantle Cell Lymphoma7 trials

Dexamethasone4 trials

Non-Small Cell Lung Cancer4 trials

Patients With Advanced Solid Tumors3 trials

AL amyloidosis3 trials

Follicular Lymphoma2 trials

Acute Lymphoblastic Leukemia2 trials

Chronic Lymphocytic Leukemia2 trials

Diffuse Large B-Cell Lymphoma2 trials

Leukemia2 trials

Acute Graft Versus Host Disease2 trials

Acute Myeloid Leukemia2 trials

Amyloidosis2 trials

Macroglobulinemia2 trials

Kidney Transplant2 trials

Relapsed or Refractory2 trials

Advanced Malignancies1 trial

Allograft1 trial

TED1 trial

Hypophosphatasia1 trial

Maintenance Therapy1 trial

Refractory1 trial

Immune Thrombocytopenia1 trial

Other Solid Tumors1 trial

Hematologic Malignancies1 trial

T-cell acute lymphoblastic leukemia1 trial

Glioblastoma Multiforme1 trial

Efficacy and Safety1 trial

Peripheral Neuropathy1 trial

Chemotherapy1 trial

Glioma1 trial

First-line Treatment1 trial

Waldenstrom macroglobulinemia1 trial

Cutaneous T-cell lymphoma1 trial

Solid Tumors1 trial

Heart Transplant1 trial

EBV1 trial

Plasma Cell Leukemia1 trial

Advanced NSCLC1 trial

Rheumatoid Arthritis1 trial

Renal Failure1 trial

Graft Vs Host Disease1 trial

Renal insufficiency1 trial

Soft Tissue Sarcoma1 trial

Treatment1 trial

Kidney Cancer1 trial

Trial1 trial

Bone Marrow Cancer1 trial

Patients With Solid Tumors1 trial

Children1 trial

Metastatic1 trial

Neuroblastoma1 trial

Newly Diagnosed1 trial

Melanoma1 trial

Complication1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Daratumumab1 trial

Intrahepatic Cholangiocellular Carcinoma1 trial

Advanced Stage1 trial

Myelodysplastic Syndromes1 trial

Transplantation1 trial

Myeloma1 trial

Malignant Solid Tumors1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News